ARCA biopharma, Inc

(NASDAQ:ABIO)

Latest On ARCA biopharma, Inc (ABIO):

Date/Time Type Description Signal Details
2023-04-25 02:30 ESTNewsARCA biopharma GAAP EPS of -$0.09N/A
2022-10-29 02:46 ESTNewsARCA biopharma GAAP EPS of -$0.16N/A
2022-08-03 02:31 ESTNewsARCA biopharma GAAP EPS of -$0.22N/A
2022-05-04 02:46 ESTNewsARCA biopharma: Activist's Pressure Could Make This Into A Liquidation PlayN/A
2022-05-03 08:46 ESTNewsARCA biopharma GAAP EPS of -$0.23N/A
2022-04-19 02:15 ESTNewsARCA biopharma establishes special board committee to evaluate strategic optionsN/A
2022-04-01 02:01 ESTNewsArca biopharma fails to meet key goal in mid-stage trial for COVID-19 therapyN/A
2022-03-14 23:00 ESTNewsARCA biopharma GAAP EPS of -$1.39N/A
2021-12-02 12:16 ESTNewsARCA Bio completes enrollment in mid-stage rNAPc2 trail in COVID-19N/A
2021-10-29 13:17 ESTNewsARCA biopharma shares surge 30% on positive DSMC recommendation for rNAPc2 COVID-19 trialN/A
2021-09-16 14:02 ESTNewsARCA Biopharma enrolls first international patient in mid-stage COVID-19 trialN/A
2021-08-23 22:32 ESTNewsARCA biopharma (ABIO) Investor Presentation - SlideshowN/A
2021-08-09 22:18 ESTNewsARCA Biopharma submits PCT patent application for rNAPc2 in COVID-19N/A
2021-08-04 22:46 ESTNewsARCA biopharma reports Q2 resultsN/A
2021-07-20 17:31 ESTNewsARCA Bio inks rNAPc2 COVID-19 patent assignment dealN/A
2021-07-20 17:27 ESTNewsARCA Bio updates on mid-stage rNAPc2 study in COVID-19, shares down 9%N/A
2021-05-03 17:00 ESTNewsARCA Biopharma names Jeff Dekker as chief financial officerN/A
2021-03-19 10:47 ESTNewsARCA biopharma reports FY resultsN/A
2020-12-16 01:18 ESTNewsEnrollment underway in ARCA bio's mid-stage AB201 study in COVID-19N/A
2020-11-25 11:01 ESTFinancialsCompany financials have been released.Neutral
2020-11-24 12:35 ESTNewsARCA Biopharma wins FDA Fast Track status for experimental COVID treatmentN/A
2020-11-07 15:00 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 03:00 ESTFinancialsCompany financials have been released.Neutral
2020-11-04 07:00 ESTFinancialsCompany financials have been released.Neutral
2020-11-02 17:25 ESTNewsARCA biopharma reports Q3 resultsN/A
2020-11-01 15:00 ESTFinancialsCompany financials have been released.Neutral
2020-10-07 09:01 ESTNewsARCA biopharma on go with mid-stage study for AB201 in COVID-19N/A
2020-09-25 16:45 ESTInsider TradeROBERT E CONWAY has directly acquired 5,000 shares and currently holds 20,000 shares.Buy
2020-09-24 16:30 ESTInsider TradeROBERT E CONWAY has directly acquired 3,056 shares and currently holds 15,000 shares.Buy
2020-09-21 17:15 ESTInsider TradeROBERT E CONWAY has directly acquired 10,000 shares and currently holds 11,944 shares.Buy
2020-09-21 12:48 ESTNewsARCA biopharma files to commence AB201 study for COVID-19N/A
2020-08-13 10:05 ESTNewsARCA biopharma readies mid-stage study of AB201 in COVID-19N/A
2020-08-08 00:00 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 09:04 ESTNewsARCA biopharma EPS beats by $1.85N/A
2020-07-23 16:02 ESTFinancialsCompany financials have been released.Neutral
2020-07-15 06:02 ESTNewsArca biopharma ups stock sales agreement with JonesTradingN/A
2020-06-02 04:00 ESTEarnings EstimateAn EPS average of -$2.51 is estimated for the quarter ending on September 30, 2020.Sell
2020-06-01 17:54 ESTNewsARCA bio plummets 20% on $9.4M direct offeringN/A
2020-05-28 09:43 ESTNewsARCA Bio launches AB201 program in COVID-19N/A
2020-05-10 00:01 ESTFinancialsCompany financials have been released.Neutral
2020-05-09 22:17 ESTNewsMixed shelf filings rise as companies prepare to raise capitalN/A
2020-05-07 07:05 ESTNewsARCA biopharma EPS beats by $1.21N/A
2020-04-10 16:00 ESTNewsARCA biopharma EPS beats by $0.27N/A
2020-04-09 08:00 ESTFinancialsCompany financials have been released.Neutral
2020-02-27 15:19 ESTEarnings EstimateAn EPS average of -$8.80 is estimated for the 2021 year.Sell
2020-02-27 15:19 ESTAnalyst RatingThe Analyst Target Price has decreased from $7.5 to $7.Neutral
2020-02-21 23:00 ESTFinancialsCompany financials have been released.Neutral
2020-02-20 11:15 ESTEarningsEarnings have been released on February 26, 2009, with -$103,560.84 earnings per share.Buy
2020-02-20 11:15 ESTEarningsEarnings have been released on October 31, 2008, with -$128,853.04 earnings per share.Buy
2020-01-21 19:00 ESTEarningsEarnings have been released on November 6, 2019, with -$0.76 earnings per share.Buy

About ARCA biopharma, Inc (ABIO):

ARCA biopharma, Inc. operates as a biopharmaceutical company applying a precision medicine approach to developing and commercializing genetically targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride) is pharmacogenetically-targeted beta-adrenergic receptor antagonist, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of AB171, a thiol-substituted isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

ABIO Quotes by TradingView

See Advanced Chart

General

  • Name ARCA biopharma, Inc
  • Symbol ABIO
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 13
  • Last Split Factor1:18
  • Last Split Date2019-04-04
  • Fiscal Year EndDecember
  • IPO Date1997-08-08
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://arcabio.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 0.77
  • Enterprise Value EBITDA 2.16
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Return on Assets -12%
  • Return on Equity -20%
  • Earnings Per Share -$6.67
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 37.85 million
  • EBITDA -6456000
  • Analyst Target Price $7
  • Book Value Per Share $5.43
View More

Share Statistics

  • Shares Outstanding 9.32 million
  • Shares Float 9.28 million
  • % Held by Insiders 40%
  • % Held by Institutions 8.43%
  • Shares Short 197614
  • Shares Short Prior Month 119719
  • Short Ratio 0.13
  • Short % of Float 2%
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta 2.77
  • 52 Week High $10.25
  • 52 Week Low $2.51
  • 50 Day Moving Average 4.51
  • 200 Day Moving Average 4.36
View More

Dividends

  • Dividend Date 2019-04-04
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

ARCA biopharma, Inc (ABIO) Dividend Calendar:

ABIO's last dividend payment was made to shareholders on April 4, 2019.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

ARCA biopharma, Inc (ABIO) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-02$N/A-$0.33
2020-06-302020-08-05$N/A-$0.73-$2.5871.71%
2020-03-312020-05-06$N/A-$0.83-$2.0459.31%
2019-12-312020-02-18$N/A-$0.69-$0.9930.3%
2019-09-302019-11-06$N/A-$0.76-$1.3041.54%
2019-06-302019-08-01$N/A-$1.14-$1.8638.71%
2019-03-312019-05-08$N/A-$1.86-$1.986.06%
2018-12-312019-02-27$N/A-$1.80-$2.5228.57%
2018-09-302018-11-14$N/A-$1.98-$3.4242.11%
2018-06-302018-08-09$N/A-$2.70-$3.9631.82%
2018-03-312018-05-08$N/A-$3.60-$3.600%
2017-12-312018-03-22$N/A-$6.12-$9.3634.62%
2017-09-302017-11-09$N/A-$7.02
2017-06-302017-08-03$N/A-$10.66
2017-03-312017-05-15$N/A-$8.59
2016-12-312017-03-21$N/A-$8.41
2016-09-302016-11-14$N/A-$9.25
2016-06-302016-08-09$N/A-$7.73
2016-03-312016-05-11$N/A-$7.25
2015-12-312016-03-17$N/A-$6.30
2015-09-302015-11-13$N/A-$5.61
2015-06-302015-08-12$N/A-$12.38
2015-03-312015-05-13$N/A-$16.33
2014-12-312015-03-20$N/A-$15.55
2014-09-302014-11-13$N/A-$13.69
2014-06-302014-08-14$N/A-$14.42
2014-03-312014-05-14$N/A-$16.02
2013-12-312014-03-21$N/A-$23.66
2013-09-302013-11-13$N/A-$20.04
2013-06-302013-08-14$N/A-$82.19
2013-03-312013-05-14$N/A-$44.47
2012-12-312013-02-28$N/A-$47.60
2012-09-302012-11-02$N/A-$51.15
2012-06-302012-08-07$N/A-$71.21
2012-03-312012-05-08$N/A-$87.43
2011-12-312012-03-01$N/A-$122.76
2011-09-302011-10-28$N/A-$131.19
2011-06-302011-08-09$N/A$21.68
2011-03-312011-05-10$N/A-$188.77
2010-12-312011-03-03$N/A-$141.76
2010-09-302010-10-29$N/A-$180.56
2010-06-302010-08-10$N/A-$196.51
2010-03-312010-05-11$N/A-$242.32
2009-12-312010-02-25$N/A-$659.39
2009-09-302009-10-30$N/A-$429.88
2009-06-302009-08-11$N/A-$858.09
2009-03-312009-05-08$N/A$965.51
2008-12-312009-02-26$15.25 million-$103,560.84
2008-09-302008-10-30$N/A-$2,419.20-$2,872.8015.79%
2008-06-302008-07-23$N/A-$82,015.77-$2,721.60-2913.51%
2008-03-312008-05-08$N/A-$5,140.80-$4,536.00-13.33%
2007-12-312008-02-27$46.86 million-$3,326.40-$4,006.8016.98%
2007-09-302007-11-01$N/A-$4,082.40-$3,723.30-9.64%
2007-06-302007-08-01$N/A$8,164.80-$4,300.80289.84%
2007-03-312007-05-09$N/A-$4,384.80-$4,460.401.69%
2006-12-312007-02-27-$6,199.20-$6,598.806.06%
2006-09-302006-11-02-$7,711.20-$5,670.00-36%
2006-06-302006-08-03-$5,443.20-$5,644.803.57%
2006-03-312006-05-05-$6,048.00-$4,418.40-36.88%
2005-12-312006-02-27-$7,408.80-$7,063.20-4.89%
2005-09-302005-11-01-$6,652.80-$6,559.75-1.42%
2005-06-302005-08-04-$6,048.00-$6,615.008.57%
2005-03-312005-05-02-$5,896.80-$6,091.203.19%
2004-12-312005-02-15-$6,048.00-$9,256.8034.66%
2004-09-302004-11-09-$5,140.80-$4,968.00-3.48%
2004-06-302004-08-09-$5,140.80-$5,473.446.08%
2004-03-312004-05-06-$9,828.00-$5,292.00-85.71%
2003-12-312004-02-05-$5,443.20-$5,216.40-4.35%
2003-09-302003-10-30-$7,711.20-$4,989.60-54.55%
2003-06-302003-07-31-$8,164.80-$9,979.2018.18%
2003-03-312003-05-01-$12,410.53
2002-09-302002-10-24-$2,876.42
2002-06-302002-07-25-$16,590.15
2002-03-312002-04-25-$45,913.37
2001-12-312002-02-06-$27,664.40
2001-09-302001-10-25-$26,839.19
2001-06-302001-06-30-$24,866.74
2001-03-312001-03-31-$22,046.91
2000-12-312000-12-31-$22,222.22
2000-09-302000-10-26-$13,608.00-$17,236.8021.05%
1999-12-312000-02-03-$17,690.40-$18,597.604.88%
1999-09-301999-11-02-$14,968.80-$17,236.8013.16%
1998-12-311999-02-11-$14,968.80-$11,793.60-26.92%
1998-09-301998-10-29-$19,051.20-$11,566.80-64.71%
1998-06-301998-07-30-$14,061.60-$12,020.40-16.98%
1998-03-311998-04-30-$9,525.60-$11,793.6019.23%
1997-12-311998-02-02-$5,443.20-$8,164.8033.33%
1997-09-301997-10-21-$6,804.00-$5,670.00-20%

ARCA biopharma, Inc (ABIO) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

ARCA biopharma, Inc (ABIO) Chart:

ARCA biopharma, Inc (ABIO) News:

Below you will find a list of latest news for ARCA biopharma, Inc (ABIO) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

ARCA biopharma, Inc (ABIO) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-172.50.77CALL0 152225.4TRUE00
2024-05-1750.05CALL120 1400105.48FALSE0.050
2024-05-177.50.04CALL0 190FALSE00
2024-05-172.50.1PUT179 735127.04FALSE00
2024-05-1750PUT0 0153.36TRUE00
2024-05-177.50PUT0 0435.9TRUE00
2024-06-212.50.97CALL5 19965.79TRUE0.970
2024-06-2150.13CALL7 1491.99FALSE-0.01-0.07
2024-06-217.50CALL0 00FALSE00
2024-06-212.50.15PUT0 27699.82FALSE00
2024-06-2152PUT0 12140.8TRUE00
2024-06-217.53.7PUT0 2301.27TRUE00
2024-09-202.51.2CALL2 22081.88TRUE1.20
2024-09-2050.25CALL0 1189.72FALSE00
2024-09-207.50.25CALL0 30103.24FALSE00
2024-09-202.50.45PUT0 794.92FALSE00
2024-09-2052.4PUT0 1088.1TRUE00
2024-09-207.50PUT0 0111.63TRUE00
2024-12-202.50CALL0 00TRUE00
2024-12-2050CALL0 00FALSE00
2024-12-207.50CALL0 00FALSE00
2024-12-202.50PUT0 00FALSE00
2024-12-2050PUT0 0135.36TRUE00
2024-12-207.50PUT0 0115.39TRUE00

Latest ABIO Trades:

Date Shares Price
Jun 13, 2022 1:50 PM EST26$2.3
Jun 13, 2022 1:50 PM EST74$2.3

ARCA biopharma, Inc (ABIO) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-02424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/907654/000156459020031694/0001564590-20-031694-index.htm
2020-05-14UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/907654/000000000020004302/0000000000-20-004302-index.htm
2018-02-05SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/907654/000003877718000045/0000038777-18-000045-index.htm
2018-03-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/907654/000003877718000149/0000038777-18-000149-index.htm
2019-02-12SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/907654/000103738919000002/0001037389-19-000002-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/907654/000103738920000132/0001037389-20-000132-index.htm
2018-03-05SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/907654/000107261318000184/0001072613-18-000184-index.htm
2018-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/907654/000110465918008484/0001104659-18-008484-index.htm
2018-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/907654/000110465918009147/0001104659-18-009147-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/907654/000110465919007350/0001104659-19-007350-index.htm
2020-01-24SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/907654/000110465920006493/0001104659-20-006493-index.htm
2018-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/907654/000114420418009015/0001144204-18-009015-index.htm
2018-04-18DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/907654/000119312518120604/0001193125-18-120604-index.htm
2018-04-18DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/907654/000119312518120614/0001193125-18-120614-index.htm
2018-09-10PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/907654/000119312518270139/0001193125-18-270139-index.htm
2018-09-20DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/907654/000119312518278722/0001193125-18-278722-index.htm
2019-01-25424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/907654/000119312519017177/0001193125-19-017177-index.htm
2019-03-11424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/907654/000119312519070964/0001193125-19-070964-index.htm
2019-05-09424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/907654/000119312519143045/0001193125-19-143045-index.htm
2019-05-20424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/907654/000119312519151798/0001193125-19-151798-index.htm
2019-06-28424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/907654/000119312519186177/0001193125-19-186177-index.htm
2020-02-26S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/907654/000119312520050219/0001193125-20-050219-index.htm
2020-05-07S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/907654/000119312520136266/0001193125-20-136266-index.htm
2020-05-18CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/907654/000119312520145073/0001193125-20-145073-index.htm
2020-06-03424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/907654/000119312520159219/0001193125-20-159219-index.htm
2018-02-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/907654/000120919118013927/0001209191-18-013927-index.htm
2018-02-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/907654/000120919118013928/0001209191-18-013928-index.htm
2018-02-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/907654/000120919118013931/0001209191-18-013931-index.htm
2018-02-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/907654/000120919118013932/0001209191-18-013932-index.htm
2018-02-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/907654/000120919118013935/0001209191-18-013935-index.htm
2018-02-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/907654/000120919118013936/0001209191-18-013936-index.htm
2018-02-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/907654/000120919118013937/0001209191-18-013937-index.htm
2018-02-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/907654/000120919118013939/0001209191-18-013939-index.htm
2018-02-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/907654/000120919118013940/0001209191-18-013940-index.htm
2018-02-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/907654/000120919118013942/0001209191-18-013942-index.htm
2018-03-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/907654/000120919118015074/0001209191-18-015074-index.htm
2018-03-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/907654/000120919118015077/0001209191-18-015077-index.htm
2018-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/907654/000120919118016685/0001209191-18-016685-index.htm
2018-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/907654/000120919118016689/0001209191-18-016689-index.htm
2018-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/907654/000120919118016691/0001209191-18-016691-index.htm
2018-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/907654/000120919118016693/0001209191-18-016693-index.htm
2018-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/907654/000120919118016698/0001209191-18-016698-index.htm
2018-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/907654/000120919118023118/0001209191-18-023118-index.htm
2018-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/907654/000120919118023122/0001209191-18-023122-index.htm
2020-09-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/907654/000120919120051302/0001209191-20-051302-index.htm
2020-09-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/907654/000120919120051890/0001209191-20-051890-index.htm
2020-09-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/907654/000120919120052094/0001209191-20-052094-index.htm
2020-06-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/907654/000138713120005573/0001387131-20-005573-index.htm
2018-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/907654/000145817718000001/0001458177-18-000001-index.htm
2020-06-01SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/907654/000153561020000096/0001535610-20-000096-index.htm
2018-01-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459018000237/0001564590-18-000237-index.htm
2018-02-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459018003257/0001564590-18-003257-index.htm
2018-03-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459018004399/0001564590-18-004399-index.htm
2018-03-2210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/907654/000156459018006566/0001564590-18-006566-index.htm
2018-03-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459018006579/0001564590-18-006579-index.htm
2018-04-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459018008254/0001564590-18-008254-index.htm
2018-04-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459018008752/0001564590-18-008752-index.htm
2018-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/907654/000156459018011830/0001564590-18-011830-index.htm
2018-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459018011864/0001564590-18-011864-index.htm
2018-05-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459018014531/0001564590-18-014531-index.htm
2018-06-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459018015077/0001564590-18-015077-index.htm
2018-07-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459018018114/0001564590-18-018114-index.htm
2018-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/907654/000156459018021065/0001564590-18-021065-index.htm
2018-08-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459018021090/0001564590-18-021090-index.htm
2018-09-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459018023272/0001564590-18-023272-index.htm
2018-10-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459018024081/0001564590-18-024081-index.htm
2018-10-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459018024466/0001564590-18-024466-index.htm
2018-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/907654/000156459018029560/0001564590-18-029560-index.htm
2018-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459018029594/0001564590-18-029594-index.htm
2018-12-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459018031208/0001564590-18-031208-index.htm
2019-01-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459019001155/0001564590-19-001155-index.htm
2019-02-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459019003354/0001564590-19-003354-index.htm
2019-02-2710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/907654/000156459019004882/0001564590-19-004882-index.htm
2019-02-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459019004936/0001564590-19-004936-index.htm
2019-03-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459019007204/0001564590-19-007204-index.htm
2019-03-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459019008641/0001564590-19-008641-index.htm
2019-04-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459019010715/0001564590-19-010715-index.htm
2019-04-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459019010923/0001564590-19-010923-index.htm
2019-04-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459019012247/0001564590-19-012247-index.htm
2019-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/907654/000156459019017210/0001564590-19-017210-index.htm
2019-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459019017283/0001564590-19-017283-index.htm
2019-05-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459019017999/0001564590-19-017999-index.htm
2019-05-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459019019829/0001564590-19-019829-index.htm
2019-06-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459019024070/0001564590-19-024070-index.htm
2019-08-0110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/907654/000156459019027966/0001564590-19-027966-index.htm
2019-08-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459019028011/0001564590-19-028011-index.htm
2019-10-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459019036859/0001564590-19-036859-index.htm
2019-10-25DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/907654/000156459019037938/0001564590-19-037938-index.htm
2019-10-25DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/907654/000156459019037939/0001564590-19-037939-index.htm
2019-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459019041036/0001564590-19-041036-index.htm
2019-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/907654/000156459019041051/0001564590-19-041051-index.htm
2019-12-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459019045742/0001564590-19-045742-index.htm
2020-02-1810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/907654/000156459020005032/0001564590-20-005032-index.htm
2020-02-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459020005048/0001564590-20-005048-index.htm
2020-03-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459020008703/0001564590-20-008703-index.htm
2020-05-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/907654/000156459020021946/0001564590-20-021946-index.htm
2020-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459020021999/0001564590-20-021999-index.htm
2020-05-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459020027369/0001564590-20-027369-index.htm
2020-06-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459020027745/0001564590-20-027745-index.htm
2020-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459020028159/0001564590-20-028159-index.htm
2020-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459020031680/0001564590-20-031680-index.htm
2020-07-02424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/907654/000156459020031694/0001564590-20-031694-index.htm
2020-07-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459020032355/0001564590-20-032355-index.htm
2020-07-14424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/907654/000156459020032360/0001564590-20-032360-index.htm
2020-07-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459020033048/0001564590-20-033048-index.htm
2020-07-22424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/907654/000156459020033060/0001564590-20-033060-index.htm
2020-08-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/907654/000156459020036784/0001564590-20-036784-index.htm
2020-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459020036857/0001564590-20-036857-index.htm
2020-08-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459020039733/0001564590-20-039733-index.htm
2020-08-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459020042033/0001564590-20-042033-index.htm
2020-09-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459020044129/0001564590-20-044129-index.htm
2020-10-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459020045968/0001564590-20-045968-index.htm
2020-10-28DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/907654/000156459020048346/0001564590-20-048346-index.htm
2020-10-28DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/907654/000156459020048349/0001564590-20-048349-index.htm
2020-11-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/907654/000156459020049634/0001564590-20-049634-index.htm
2020-11-0210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/907654/000156459020049656/0001564590-20-049656-index.htm
2020-05-20EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/907654/999999999520001219/9999999995-20-001219-index.htm
2018-05-10CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/907654/999999999718005653/9999999997-18-005653-index.htm
2019-05-17CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/907654/999999999719004572/9999999997-19-004572-index.htm

ARCA biopharma, Inc (ABIO) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of ARCA biopharma, Inc (ABIO). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 40%
Institutional Ownership: 843%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-02-26Anthony A. Jr. Florence10% Share HolderSell1,460,209.000.50731,272.670.00https://www.sec.gov/Archives/edgar/data/907654/000120919118013932/0001209191-18-013932-index.htm
2018-04-02Brian L. SelbyVP, FinanceSell1,114.000.50556.330.00https://www.sec.gov/Archives/edgar/data/907654/000120919118023118/0001209191-18-023118-index.htm
2018-02-26DAVID M MOTT10% Share HolderSell1,460,209.000.50731,272.670.00https://www.sec.gov/Archives/edgar/data/907654/000120919118013936/0001209191-18-013936-index.htm
2018-02-26FOREST BASKETT10% Share HolderSell1,460,209.000.50731,272.670.00https://www.sec.gov/Archives/edgar/data/907654/000120919118013931/0001209191-18-013931-index.htm
2018-02-26Growth Equity Opportunities IV, LLC10% Share HolderSell1,460,209.000.50731,272.670.00https://www.sec.gov/Archives/edgar/data/907654/000120919118013927/0001209191-18-013927-index.htm
2018-02-27HEALTHCARE CAPITAL PARTNERS LP VENROCK10% Share HolderSell41,331.000.5321,905.430.00https://www.sec.gov/Archives/edgar/data/907654/000145817718000001/0001458177-18-000001-index.htm
2018-02-26Jon Sakoda10% Share HolderSell1,460,209.000.50731,272.670.00https://www.sec.gov/Archives/edgar/data/907654/000120919118013937/0001209191-18-013937-index.htm
2018-02-26JOSHUA MAKOWER10% Share HolderSell1,460,209.000.50731,272.670.00https://www.sec.gov/Archives/edgar/data/907654/000120919118013935/0001209191-18-013935-index.htm
2018-02-26PETER J BARRIS10% Share HolderSell1,460,209.000.50731,272.670.00https://www.sec.gov/Archives/edgar/data/907654/000120919118013928/0001209191-18-013928-index.htm
2018-02-26Peter W. Sonsini10% Share HolderSell1,460,209.000.50731,272.670.00https://www.sec.gov/Archives/edgar/data/907654/000120919118013940/0001209191-18-013940-index.htm
2018-02-26Ravi Viswanathan10% Share HolderSell1,460,209.000.50731,272.670.00https://www.sec.gov/Archives/edgar/data/907654/000120919118013942/0001209191-18-013942-index.htm
2018-02-26SCOTT D SANDELL10% Share HolderSell1,460,209.000.50731,272.670.00https://www.sec.gov/Archives/edgar/data/907654/000120919118013939/0001209191-18-013939-index.htm
2018-02-27Brian L. SelbyVP, FinanceSell161.000.5385.331,114.00https://www.sec.gov/Archives/edgar/data/907654/000120919118015074/0001209191-18-015074-index.htm
2020-09-21ROBERT E CONWAYDirectorBuy10,000.004.7747,660.0011,944.00https://www.sec.gov/Archives/edgar/data/907654/000120919120051302/0001209191-20-051302-index.htm
2018-04-03Thomas A KeuerChief Operating OfficerSell482.000.50241.7213,153.00https://www.sec.gov/Archives/edgar/data/907654/000120919118023122/0001209191-18-023122-index.htm
2018-02-28Thomas A KeuerChief Operating OfficerSell410.000.72294.3813,635.00https://www.sec.gov/Archives/edgar/data/907654/000120919118015077/0001209191-18-015077-index.htm
2020-09-22ROBERT E CONWAYDirectorBuy3,056.004.6614,240.6515,000.00https://www.sec.gov/Archives/edgar/data/907654/000120919120051890/0001209191-20-051890-index.htm
2020-09-25ROBERT E CONWAYDirectorBuy5,000.004.2821,399.5020,000.00https://www.sec.gov/Archives/edgar/data/907654/000120919120052094/0001209191-20-052094-index.htm
2018-02-26HEALTHCARE CAPITAL PARTNERS LP VENROCK10% Share HolderSell1,500,000.000.55825,000.0041,331.00https://www.sec.gov/Archives/edgar/data/907654/000145817718000001/0001458177-18-000001-index.htm